Global Drugmakers Eye More China Biotech Deals After Record Year

Why It Matters

The surge in China‑centric licensing and investment deals reshapes global drug pipelines and signals a shift of bargaining power toward Chinese innovators, while the cooling IPO market forces stricter due‑diligence on emerging biotech ventures.

Key Takeaways

• 2025 out‑licensing deals reached $135.7 billion, nearly triple 2024.
• Johnson & Johnson and Merck plan deeper China presence and newco investments.
• AstraZeneca paid $1.2 billion upfront to CSPC, potential $17.3 billion milestones.
• Sanofi’s rovadicitinib licensing deal valued up to $1.5 billion.
• HKEX Chapter 18A listings surged, yet many biotech IPOs trade below offer.

Pulse Analysis

China’s biopharma sector has become a magnet for global drugmakers seeking the next blockbuster, driven by a record $135.7 billion in out‑licensing activity in 2025. The sheer scale—almost three times the previous year—reflects both the rapid scientific output of Chinese biotech firms and their ability to negotiate from a position of financial strength. Companies such as Johnson & Johnson and Merck are not only licensing promising candidates but also committing capital through "newco" structures, ensuring they retain equity upside and deeper integration with Chinese research pipelines.

High‑profile deals underscore the new valuation benchmarks. AstraZeneca’s $1.2 billion upfront payment to CSPC, with potential milestone payouts exceeding $17 billion, and Sanofi’s $1.5 billion licensing of Sino Biopharma’s rovadicitinib illustrate how Western giants are willing to front substantial sums for access to innovative obesity, diabetes, and inflammatory‑disease candidates. These agreements also provide Chinese firms with rapid cash infusion, bolstering their credibility and enabling further R&D investment, often augmented by artificial‑intelligence‑driven discovery platforms that are reshaping the drug development landscape.

However, the financing environment is showing early signs of moderation. Hong Kong’s Chapter 18A listings, designed to give pre‑revenue biotech firms a public market runway, have proliferated, yet several recent IPOs—including Mabwell Bioscience—saw shares trade below offering prices. Regulators are tightening listing standards, prompting investors to demand stronger scientific differentiation and experienced management teams. This emerging rigor may temper the frenzy but will likely improve the overall quality of Chinese biotech ventures entering the global market, benefiting both investors and pharmaceutical partners seeking sustainable innovation pipelines.